Clinical trials: Refractory Overactive Bladder
Overactive Bladder
Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?
The purpose of this research study is to help determine if 10 injections of Botox ® 100 units is less painful than 20 injections of Botox ® 100 units based on effectiveness in reducing urge incontinence episodes.
- Trial name
- NCT04124939
- Testing
- OnabotulinumtoxinA 100 Units
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Wake Forest University Health Sciences
Overactive Bladder
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:
- Trial name
- NCT01220726
- Testing
- Botox
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Overactive Bladder
Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Overactive bladder (OAB) is a bothered symptom syndrome. Traditional medication for OAB is antimuscarinic agent. However, adverse events such as dry mouth, constipation, blurred vision, and dizziness may prohibit patient to take…
- Trial name
- NCT01167257
- Testing
- Liposome encapsulated botulinum toxin A, Normal saline instillation
- Where
- Taiwan
- Volunteers
- 62 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Overactive Bladder
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA…
- Trial name
- NCT01089751
- Testing
- trospium chloride
- Where
- United States
- Volunteers
- 322 people
- Sponsor
- Allergan
Overactive Bladder
Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Abstract Introduction: Urgency Urinary Incontinence (UUI) is a common condition with a prevalence of 9-31% in women in the United States.
- Trial name
- PTNS-M (NCT04907032)
- Testing
- Mirabegron 50 MG, Posterior Tibial Nerve Stimulation (PTNS)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Urinary Incontinence, Urge
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
The purpose of this randomized, open-label, active-control trial is to compare the effectiveness of intra-detrusor botulinum toxin A (Botox A®, Allergan) versus sacral neuromodulation (InterStim®, Medtronic) for the treatment of…
- Trial name
- ROSETTA (NCT01502956)
- Testing
- InterStim® device, Botox® injection
- Where
- 9 sites in United States
- Volunteers
- 386 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Overactive Bladder, Urinary Incontinence
Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
The objective is to evaluate the efficacy and safety of adding mirabegron to an antimuscarinic to treat urinary incontinence in children with Overactive Bladder that are refractory to antimuscarinics.
- Trial name
- Add-on-Mira (NCT02476175)
- Testing
- Mirabegron
- Volunteers
- 35 people
- Sponsor
- CHU de Quebec-Universite Laval
Overactive Bladder
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
The goal of this study is to investigate the safety and effectiveness of a new implanted device designed to treat Urinary Urgency-Frequency Syndrome.
- Trial name
- NCT00131573
- Testing
- bion
- Where
- 11 sites in United States
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation